Skip to content 
“Because the large order volume is high and the urgent need to schedule production continuously, we arranged for front-line employees to start work one after another on the fifth day of the New Year, and made flexibly adjustments to the vacation arrangements, and made every effort to sprint for the annual order target!”
Recently, outside the tablet pressing workshop on the 3rd floor of Building B, Jiangsu Litaier Pharmaceutical Co., Ltd. (hereinafter referred to as “Litaier”) in Nanjing Jiangning Development Zone, Zhang Xiang, deputy manager of the production department, sighed that the production line was busy this year. The situation came earlier than any previous year.
It is reported that after more than 8 years of construction, Litaire, established in 2012, was acquired by Nanjing Fangshenghe Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Fangshenghe”) in 2021 with the help of ICBC Nanjing Branch. , thus starting the integrated operation model of “R&D + Production”. Today, Litel has hundreds of employees, with more than 20 independent products and entrusted products, and has developed into a national high-tech enterprise.
Zhang Xiang, who has worked in Litel for nearly 4 years, used to take a complete Spring Festival holiday. This year, not only did he come to work early in the fifth day of the New Year, but he has only been on a day off.
He said that the Yixintan (i.e., Shakubalivalsartan sodium tablets, a drug for treating hypertension and heart failure) developed by Fang Shenghe is the first domestic sakubalivalsartan sodium to break through patent barriers and legally launch it in advance. Tablets of generic drugs. The 200mg-specification Yixintan of the Litel production line for the first time in the fourth quarter of last year is also the only sodium tablet of sakubalivalsartan in the domestic market except for the original drug.This move will greatly reduce the cost of medication for patients with hypertension and heart failure, and better help medical insurance to control costs.
“In order to adapt to Yixintan’s production needs, we have made preparations in advance since the second half of last year, recruiting more than 20 front-line employees and investing nearly 10 million yuan to optimize and upgrade the original equipment in the workshop to improve production capacity.”
In the tablet press workshop behind Zhang Xiang, white tablets were constantly “spouting” from outlets on both sides of the tablet press. These tablets were transmitted to the coating workshop in an orderly manner along the arc-shaped pipeline for the next process. In other workshops, the production lines are also operating efficiently, and front-line employees are operating in an orderly manner. They work closely with the automation equipment, presenting a busy scene of full firepower.
Like Zhang Xiang, there is also Chen Ning, deputy general manager of Litaire. “In the fourth quarter of last year, our Yixintan’s production volume was less than 10 million pieces. By this year , our production plan in the first quarter has doubled several times, and it is still increasing in the second quarter…” Pointing to the commercialization on computers In the capacity calculation table, Chen Ning introduced the follow-up production plan in detail.
Currently, the production capacity of 3 million pieces per week
How to further improve
To meet production plans?
Chen Ning is confident about this. “At present, our production schedule is a one-shift system, and we plan to gradually adjust it to a two-shift system to improve the efficiency of equipment use. In addition, we also plan to add key equipment such as coating machines and pelletizers, which can meet existing orders on the one hand The production demand is also preparing for next year. “He said that order volume is expected to increase significantly next year.
Chen Ning’s prediction stems from Yixintan’s continued rising market size.
It is reported that due to the clear utility mechanism, multiple organs benefit, sakubalivalsartan sodium tablets have been recommended for hypertension treatment and the market capacity continues to expand. Relevant statistics show that in the first half of last year, the domestic sales of sakubalivalsartan sodium tablets totaled 2.382 billion yuan, and is expected to hit 4.7 billion yuan throughout the year.
Against this background, since Yixintan was approved for listing, market recognition has also increased steadily. By the end of last year, Yixintan had entered more than 5,000 medical terminals of various types, with a total sales of over 100 million tablets, which was equivalent to saving medical insurance and patients with more than 50 million yuan in drug costs.
” Every city’s development has its own characteristics, and the pharmaceutical industry has always been a dominant industry in Nanjing. Yixintan is local research and development and local mass production, and is a genuine ‘Nanjing Manufacturing’. The order volume that has continued to grow since this year is Litel’s “good start” in the first quarter laid a solid foundation, and gave us greater confidence in the benefits of “Nanjing Manufacturing” to more patients.” Fang Sheng and Chairman Yuan Fang said.
